All News
ACR24 Preview Podcast (11.15.2024)
ACR 2024 starts tomorrow. Here are a few previews of abstracts to be presented, along with my recommendations of sessions you don’t want to miss.
Read Article
Weight Loss from Anti-Obesity Medications Prevents Gout
A population based study looked at the effect of the weight loss drug, Orlistat, in obese individuals. Compared to those untreated, orlistat over 1 year was associated with significant weight loss and significantly lower risks of incident gout and recurrent gout flares among overweight or obese people.
Read Article
Dr. Quotes (11.8.2024)
Dr. Jack Cush reviews the news and journal reports from this past week from RheumNow.com.
Read Article
Happy Diwali (11.1.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Read Article
Puechal et al. Serial ANCA testing may predict relapse in a large group of AAV patients but is NOT useful for individual patients. @RheumNow #ACR24 Abstr#0721 https://t.co/ClvTk2Tlar https://t.co/k4vc7l9jzK
Links:
Richard Conway RichardPAConway ( View Tweet)
Prevalence of HLH among pts w/SLE: lower than consults would suggest!
Observational study using NIS: 139 cases out of >100k pts w/SLE (0.13%); 6 fold increase in mortality
Fits my priors; HLH is overdiagnosed, but bad when it happens
@RheumNow #ACR24 Abstr#0619 https://t.co/iz3BlUOJb9
Mike Putman EBRheum ( View Tweet)
Harkins @DrTrishHarkins et al. Serum disease activity markers in PMR. ROC analysis for active vs remission - fibrinogen (1.000), ESR (0.986), Haptoglobin (0.976), CRP (0.986), ALP (0.854). @RheumNow #ACR24 Abstr#0741 https://t.co/f8cX68Ov9Y https://t.co/zp5c7aQwxr
Links:
Richard Conway RichardPAConway ( View Tweet)
#0066
🧬Epigenetics, Gut Microbiota & RA
🔬 110 RA patients v 110 controls
🦠 Collinsella abundance a/w DNA methylation changes (PRHOXNB, TBC1D22A) in RA, correlating with disease activity.
💡❔Role of gut microbiota & epigenetic markers as RA biomarkers
#ACR24 @RheumNow https://t.co/yZn0KkRpE6
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Another abstract #0650 highlighting the impact of tubulointerstitial inflammation predicting risk of CKD/ESRD in lupus nephritis
@RheumNow #ACR24 https://t.co/XYwO0xnWNR
Akhil Sood MD AkhilSoodMD ( View Tweet)
Which lupus nephritis patients are at higher risk for CKD? #Abstract0624 shows coexisting tubulointerstitial inflammation/damage (TII/TID) on renal biopsy is linked to CKD progression (HR 2.667, 95% CI: 1.333-5.335)
Risk high among Class III, IV, V and eGFR > 30
@RheumNow #ACR24
Akhil Sood MD AkhilSoodMD ( View Tweet)
171 SSc pts w/ hand Xrays and US found 20% w/ Joint involvement. Active Synovitis & tenosynovitis predicted by CRP>10mg/L (p = 0.013), fibrotic tenosynovitis on US (p = 0.005), anti-RNA polymerase III antibodies (p = 0.043) https://t.co/OIornA9sAA https://t.co/yXyX5k2yqD
Dr. John Cush RheumNow ( View Tweet)
An Artificial Intelligence-Based Gout Management System Reduced Chronic Kidney Disease Incident and Improves achieving Target Serum Urate levels. AI lowered incid. of CKD stage≥ 3 by 47%, & incr # achieving target SUA <6mg/dl with(59% vs 26%, p<0.001). https://t.co/INULBvaKF9 https://t.co/fkPgbscOXj
Dr. John Cush RheumNow ( View Tweet)
Study of at-risk & early RA Synovium suggests an early pathogenic myeloid signature (IL-1B+CCL20+ & SPP1+MT2A+ macrophage clusters) before disease onset. These display heightened CD40 expression, capable of shaping stromal cell responses https://t.co/CYmb1ro9g9 https://t.co/9pXbqHaQ2G
Dr. John Cush RheumNow ( View Tweet)
Cross-sectional study of 176 CASPAR+ PsA patients correlated Dz activity (cDAPSA) w/ SAA, IL-8, IP10 (IFNg/CXCL10), M-CSF, SCGF-β, SDF-1α) (AUC 0.802- 0.835). The panel was significantly better than CRP (AUC = 0.727, p = 0.022). https://t.co/AZq81S6NH0 https://t.co/5eI241gLVj
Links:
Dr. John Cush RheumNow ( View Tweet)
Hydroxychloroquine effects studied in 30pts (23 RA, 7SLE). Results did not support that HCQ may reduce CV risk - Arterial stiffness was not affected by HCQ, HCQ modestly lowered HbA1c & lipids - yet HCQ has been shown to reduced CV risk in observational studies… https://t.co/n283HwvRm4 https://t.co/lQN342uevy
Dr. John Cush RheumNow ( View Tweet)
Psoriasis pts w/ Arthralgia referred for Rheum Eval - 1419 referred pts, 8.4% (119) met at risk for PsA criteria, and 29% (35) developed PsA w/in 1yr. Predictors included +FHx PsO, Ultrasound synovitis or enthesopathy findings, & low tender joint count. https://t.co/Fxgiu6D72j https://t.co/b8dMCOC18F
Dr. John Cush RheumNow ( View Tweet)
How would you treat an anti-synthetase overlap pt w/ myositis, polysynovitis & rapid ILD (pt on steroids)?
Dr. John Cush RheumNow ( View Tweet)
Surprise! Low-level proteinuria is more associated w/ proliferative LN and adverse long-term outcomes. Study of 249 SLE GN pts (median 33 yrs; proteinuria =2.2/D; 71% proliferative (PGN)
- 60% PGN w ≤1 g/d proteinuria (more renal recovery)
- 79% w/ 1-3g/d
- 71% w/ ≥3 g/d… https://t.co/t0aqWn3NDS https://t.co/zqJlJfHzqU
Dr. John Cush RheumNow ( View Tweet)
Real-world study of 76 #PsA pts (Dz Duration Psoriasis 216 mos, PsA 120 mos. No correlatons seen between skin/PASI scores and PsA clinical variables, except the signif correlation betw PASI & enthesitis (ρ = 0.285; p = 0.013). https://t.co/K6FXjE5A4N https://t.co/NVlPiPVT0s
Dr. John Cush RheumNow ( View Tweet)
Biomarkers in ILD: Small cohort study of 55 pts suggest potential biomakers: Cancer antigen 15-3, MMP-7, Surfactant protein D, MIP-1β, & chitinase 3-like protein-1 (YKL-40). https://t.co/S5bokc0SNi https://t.co/kLKjnyuK8p
Links:
Dr. John Cush RheumNow ( View Tweet)
